Neurofilament protein in cerebrospinal fluid: A marker of white matter changes

Journal of Neuroscience Research

Volumn 66, Issue 3, 2001, Pages 510-516

  Sjgren, M ^a,d   Blomberg, M ^b   Jonsson, M ^a   Wahlund, L O ^b   Lind, K ^a   Rosengren, L ^a   Blennow, K ^a,c   Wallin, A ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c MEDICAL RESEARCH COUNCIL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Axonal degeneration; Dementia; White matter

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; NEUROFILAMENT PROTEIN; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MULTIINFARCT DEMENTIA; MYELINATED NERVE; NERVE FIBER DEGENERATION; NEURORADIOLOGY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; WHITE MATTER;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; CEREBRAL CORTEX; DEMENTIA, VASCULAR; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE FIBERS, MYELINATED; NEUROFILAMENT PROTEINS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; SERUM ALBUMIN; SEX FACTORS; TAU PROTEINS; WALLERIAN DEGENERATION;

EID: 0035499941     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.1242     Document Type: Article

References (59)

1. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: A community based follow up study
2. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer's disease: Differences between early- and late-onset AD and stability during the course of disease
3. Biological markers for the clinical diagnosis of Alzheimer's disease
4. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: Implications for the clinical diagnosis of Alzheimer's disease
5. Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors
6. White-matter lesions on CT in Alzheimer patients: Relation to clinical symptomatology and vascular factors
7. Protein analysis in cerebrospinal fluid: I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio
8. Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?
9. Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology
10. Frontal lobe degeneration of non-Alzheimer type revisited
11. Clinical and neuropathological criteria for frontotemporal dementia
12. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice
13. Neuropathology of white matter changes in Alzheimer's disease and vascular dementia
14. White matter changes in dementia of Alzheimer's type. Biochemical and neuropathological correlates
15. Research criteria for subcortical vascular dementia in clinical trials
16. Cerebrovascular pathology contributes to the heterogeneity of Alzheimer's disease
17. The relation of cerebral magnetic resonance signal hyperintensities to Alzheimer's disease
18. "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician
19. Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia
20. Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice
21. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease
22. High cerebrospinal fluid tau and low amyloid beta 42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
23. Tau protein and the neurofibrillary pathology of Alzheimer's disease
24. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease
25. Leuko-araiosis
26. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke
27. Full-length amyloid-beta [1-42(43)] and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques
28. Neurofilaments in health and disease
29. Longitudinal study of cerebrospinal fluid levels of tau, Abeta 1-40, and Abeta 1-42(43) in Alzheimer's disease: A study in Japan
30. Leuko-araiosis and cerebral perfusion in normal aging
31. Neurofilament protein in cerebrospinal fluid: A potential marker of activity in multiple sclerosis
32. Clinical diagnosis of Alzheimer's disease: Report on the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease
33. Reappraisal of amyotrophic lateral sclerosis with dementia
34. Vascular dementia: The role of changes in the vessels
35. Decreased beta-amyloid 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jacob disease
36. Cerebral white matter is highly vulnerable to ischemia
37. Pathogenesis of leukoaraiosis: A review
38. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop
39. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF
40. Neurofilament protein levels in CSF are increased in dementia
41. White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity
42. Heterogeneity of Alzheimer's disease
43. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
44. CSF levels of tau, B-amyloid42, and GAP-43 in frontotemporal dementia, other types of dementia and normal aging
45. Frontotemporal dementia can be distinguished from Alzheimer's disease and subcortical white matter dementia by an anterior to posterior rCBF-SPET ratio
46. The prevalence of white-matter lesions on computed tomography of the brain in demented and nondemented 85-year-olds
47. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: Relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele
48. A population study of apoE genotype at the age of 85: Relation to dementia, cerebrovascular disease, and mortality
49. Amyloid beta protein 1-42/43 (A beta 1-42/43) in cerebellar diffuse plaques: Enzyme-linked immunosorbent assay and immunocytochemical study
50. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease
51. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease
52. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease
53. Principles of albumin and IgG analysis in neurological disorders
54. Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease
55. Development of a specific diagnostic test for measurement of b-amyloid(1-42) in CSF
56. White matter low attenuation on computed tomography in Alzheimer's disease and vascular dementia - Diagnostic and pathogenetic aspects
57. Blood brain barrier function in vascular dementia
58. Symptoms, vascular risk factors, and blood-brain barrier function in relation to CT white-matter changes in dementia